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Background: The lung epithelial tissue barrier represents the main portal for entry of inhaled nanoparticles (NPs)
into the systemic circulation. Thus great efforts are currently being made to determine adverse health effects
associated with inhalation of NPs. However, to date very little is known about factors that determine the pulmonary
translocation of NPs and their subsequent distribution to secondary organs.
Methods: A novel two-step approach to assess the biokinetics of inhaled NPs is presented. In a first step, alveolar
epithelial cellular monolayers (CMLs) at the air-liquid interface (ALI) were exposed to aerosolized NPs to determine
their translocation kinetics across the epithelial tissue barrier. Then, in a second step, the distribution to secondary
organs was predicted with a physiologically based pharmacokinetic (PBPK) model. Monodisperse, spherical, well-
characterized, negatively charged gold nanoparticles (AuNP) were used as model NPs. Furthermore, to obtain a
comprehensive picture of the translocation kinetics in different species, human (A549) and mouse (MLE-12) alveolar
epithelial CMLs were exposed to ionic gold and to various doses (i.e., 25, 50, 100, 150, 200 ng/cm2) and sizes (i.e., 2,
7, 18, 46, 80 nm) of AuNP, and incubated post-exposure for different time periods (i.e., 0, 2, 8, 24, 48, 72 h).
Results: The translocation kinetics of the AuNP across A549 and MLE-12 CMLs was similar. The translocated fraction
was (1) inversely proportional to the particle size, and (2) independent of the applied dose (up to 100 ng/cm2).
Furthermore, supplementing the A549 CML with two immune cells, i.e., macrophages and dendritic cells, did not
significantly change the amount of translocated AuNP. Comparison of the measured translocation kinetics and
modeled biodistribution with in vivo data from literature showed that the combination of in vitro and in silico
methods can accurately predict the in vivo biokinetics of inhaled/instilled AuNP.
Conclusion: Our approach to combine in vitro and in silico methods for assessing the pulmonary translocation and
biodistribution of NPs has the potential to replace short-term animal studies which aim to assess the pulmonary
absorption and biodistribution of NPs, and to serve as a screening tool to identify NPs of special concern.
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Fig. 1 Transwell chamber system that was used to culture and
expose the A549 and MLE-12 CMLs. The displayed graphic shows
the CMLs at the ALI (24 h after the apical medium was removed and
the surface liquid was produced by the cells) and during/shortly
after exposure using the ALICE, when the particles settle down and
distribute between the individual compartments (surface liquid,
cellular monolayer and basolateral medium). Insert surface area:
0.9 cm2. Membrane pore size: 3 μm
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Nanomaterials are increasingly used in industrial and
consumer products [1–3], so that potentially workers
and consumers are exposed to nanomaterials from vari-
ous sources and via different routes. At the workplace,
inhalation is considered to be the primary route of ex-
posure [4]. Consumers can also be exposed to nanoma-
terials via inhalation through the use of spray products
[5–7]. After inhalation, the nanomaterials can deposit on
the lung surface and be displaced into the aqueous lining
layer, where they may then interact with epithelial cells
[8, 9]. These cells form one of the first cellular lines of
defense against inhaled nanomaterials. In the human
body, the most permeable epithelial barrier is located in
the deep lung, lining the alveoli [10]. This barrier, called
the air-blood barrier, is only 0.1 to 0.2 μm thick and con-
sists of alveolar epithelial cells type I and surfactant-
producing alveolar epithelial cells type II (AT II) [10].
Due to the physiology of the respiratory tract, the alveoli
are also the primary region where inhaled particles be-
tween 10 and 100 nm can deposit [11]. Thus, great ef-
forts have been devoted to determine adverse health
effects in the lungs caused by the inhalation of nanopar-
ticles (NPs), by both in vitro and in vivo approaches [10,
12–18]. However, little is known about the systemic ef-
fects of inhaled NPs, considering that the alveoli have
the most permeable epithelial barrier of all uptake
routes, and, inhaled NPs have been shown to reach the
systemic circulation [19–26]. Furthermore, the factors that
enable and determine the pulmonary translocation and
biodistribution of NPs are presently largely unknown.
It has been shown that the size of the deposited parti-
cles has a large influence on the translocation of NPs
through the air-blood barrier. In rats, the translocation
is increasing with decreasing particle diameter for both
gold [20, 21] and iridium [23, 24] NPs. Another factor
that influences the biokinetic behavior is the surface
modification of the respective NPs. However, regarding
the direction of this influence the literature is inconsist-
ent: While in vivo experiments with rats showed a
higher translocation for NPs with anionic surfaces as
compared to cationic surfaces [19, 20], the opposite was
found in in vitro experiments using primary alveolar
cells from mice [27] and rats [28, 29]. Furthermore, the
composition of the pulmonary surfactant layer also
seems to influence the translocation kinetics of NPs
through the air-blood barrier: After instillation of 10 μg
surfactant protein D in mice, the translocation of 22 nm
gold nanoparticles (AuNP) decreased approximately by a
factor of three after two hours of inhalation exposure
[30]. Although this decrease was not significantly differ-
ent from the control group, the results indicate that the
interaction of NPs with proteins in the pulmonary sur-
factant layer is an important factor.However, considering the large variety of NPs with
different physicochemical characteristics [4], such as
chemical composition, particle size and shape, surface
modification, aggregation/agglomeration state and spe-
cific surface area, the available studies can only be con-
sidered as very first steps towards understanding the
biokinetic fate of inhaled NPs at the lung epithelial tissue
barrier. Furthermore, apart from ethical considerations,
considerable technical and financial effort would be ne-
cessary to investigate every single type of NP in vivo
[31], hence highlighting the necessity for alternative
methods to determine the toxicokinetics of inhaled NPs.
In this study, we present a novel two-step approach to
assess the biokinetics of inhaled NPs without the use of
animal experiments, by combining in vitro with in silico
methods. To this end, first, the translocation kinetics of
AuNP across the lung epithelial tissue barrier was deter-
mined with alveolar epithelial cellular monolayers
(CMLs) at the air-liquid interface (ALI) (Fig. 1). Then, in
a second step, their biodistribution to secondary organs
was predicted with a physiologically based pharmacoki-
netic (PBPK) model (Fig. 2). The predictive capability of
this approach was evaluated by comparison to available
in vivo data from the literature [20, 30]. Furthermore, in
order to investigate different parameters that influence
the pulmonary absorption kinetics, the translocation of
AuNP was determined at various time points post-
exposure (i.e., 0, 2, 8, 24, 48, 72 h), for different exposure
doses (i.e., 25, 50, 100, 150, 200 ng/cm2) and for differ-
ent particle sizes (i.e., 2, 7, 18, 46, 80 nm). For compari-
son also ionic gold was tested.
The CMLs were exposed to AuNP using the air-liquid
interface cell exposure (ALICE) system [32]. With the
ALICE system, cells at the ALI can directly be exposed
to an NP aerosol, which is an effective way to mimic
inhalation exposure [12, 13, 32]. Adenocarcinomic human
Fig. 2 Schematic diagram of the AuNP PBPK model. Dashed lines
symbolize the translocation of AuNP through the kidneys and liver
to the urine and feces, respectively, and the translocation of AuNP
across the lung epithelial tissue barrier (*). Adapted from [39]
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were used as CMLs. Both cell types show functional
characteristics of AT II epithelial cells, including the de-
velopment of a surfactant layer [33, 34]. The production
of a protein-containing surfactant layer was considered
crucial to model the surfactant protein attachment to
the surface of the NPs. This surfactant protein-NP inter-
action may largely influence the biological properties of
NPs [35–37] and has been described to be indispensable
for in vitro studies modeling the lung [38].
To simulate the biodistribution of AuNP we adapted
our recently presented PBPK model for titanium dioxide
(TiO2) NPs [39]. The PBPK model was used in two dif-
ferent ways in this study: (1) to simulate the biodistribu-
tion of AuNP that translocate from the lung to the
blood and (2) to update the time-dependent pulmonary
translocation kinetics measured in animal studies [20,
30], which were compared to our in vitro data. The latterTable 1 Physicochemical parameters of the AuNP before and after A
AuNP diametera 2 nm
In suspension before
ALICE exposure
UV–Vis: Maximum absorption curveb [nm] No L
UV–Vis: Diameterc [nm] 1-2
DLS: Hydrodynamic diameter [nm] n.d.i





TEM: Particle diametere [nm] 2.5 ±
TEM: Circularityf [−] 0.46
Fraction of gold below 30 kDa in the
basolateral mediumg [%]
8.80
aAuNPs were ordered by size according to the UV–Vis measurements
bthe complete UV–Vis spectrum can be found in Additional file 1 (Figure S1)
cdetermined as described in Haiss et al. [72] (see Methods)
daverage zeta potential ± standard deviation (SD)
eaverage diameter ± SD as measured by TEM (n = 161 to 259). Histograms showing the
f0 corresponds to an infinitely elongated polygon; 1 corresponds to a perfect circle
gdetermined with an A529 CML 24 h after exposure to 100 ng/cm2 AuNP. Mean fra
hLSPR: localized surface plasmon resonance
inot detected (size below the LOD of the instrument)
jTHPC: tetrakis (hydroxymethyl) phosphonium chloride
kleft tail of the size distribution partly below the limit of detection (<0.9 nm). Hence
lbelow the limit of detection (LOD depends on size. Approximate LODs are 1.4 % fowas necessary, because in animal studies it is not possible
to distinguish mucociliary-cleared from biliary-cleared
AuNP in the gastrointestinal tract (GIT) and the feces.
Results
AuNP characterization
The physicochemical parameters of the AuNP used
are summarized in Table 1 (more details are given in
Additional file 1). The particles which were produced
cover the whole nano-range (1–100 nm [40]) and are
highly stable: the nebulization in the ALICE does not
alter the size of the AuNP, and we did not determine a
considerable amount of gold below 30 kDa in the
basolateral medium 24 h after the exposure in the
ALICE, hence the dissolution of particles in the trans-
well chamber system is insignificant. The relatively
high fraction of gold below 30 kDa for the 2 nm parti-
cles (8.8 %, Table 1) may be attributed to the particle
size distribution of these very small NPs, which in-
cludes significant amounts of particles smaller than
30 kDa (30 kDa corresponds to an uncoated AuNP
with a size of approximately 1.7 nm. However, the ac-
tual cut-off size is probably even lower, due to coating
effects in the medium).
CML characterization
Laser scanning microscopy (LSM) images of A549 and
MLE-12 CMLs after 24 h at the ALI and 24 h post-
exposure are depicted in Fig. 3a-d (LSM images 48 and
72 h post-exposure are provided in Additional file 1). In
the displayed orthogonal view, the confluent cellularLICE exposure
7 nm 18 nm 46 nm 80 nm
SPRh band 512 521 529 549
6-7 16-18 46 80
n.d.i 20.2 52.4 80.4
n.d.i 6.2 9.7 13.1
te-THPCj Citrate Citrate Citrate Citrate
3 ± 0.9 −50.9 ± 1.3 −31.7 ± 1.5 −32.4 ± 1.5 −27.5 ± 2.3
1.2k 6.5 ± 2.3 19.6 ± 4.2 49.1 ± 10.7 85.5 ± 14.2
± 0.13 0.60 ± 0.20 0.77 ± 0.13 0.88 ± 0.05 0.86 ± 0.10
± 0.34 0.52 ± 0.16 <LODl <LODl <LODl
complete particle size distribution can be found in Additional file 1 (Figure S2)
ction ± SD (n = 3)
, mean diameter was probably slightly overestimated; see also Additional file 1
r 18 nm, 1.2 % for 46 nm, 2.3 % for 80 nm)
Fig. 3 LSM images of cytoskeletal F-actin (green) and the cell nuclei (grey). Orthogonal view of the A549 CML after (a) 24 and (b) 48 h, and of
the MLE-12 CML after (c) 24 and (d) 48 h at the ALI. (b, d) After 24 h at the ALI the CML were exposed to 100 ng/cm2 of 18 nm large AuNP.
Within the blue circle the top view on the CML is depicted
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both cell types, the CML was well-developed on the en-
tire membrane surface.
The measured surface liquid height on the MLE-12
cells was 68 ± 14 μm (mean ± SD) after 24 h at the ALI.
The surface liquid height for the A549 CML was below
10 μm (limit of detection; LOD). Hence, the total surface
liquid height on MLE-12 CMLs is approximately four
times higher than on A549 CMLs, when the 14 μm li-
quid film that is formed after nebulization of the AuNP
suspension in the ALICE is also considered [32].
The integrity of the CMLs was evaluated by assessing
the permeability to Blue Dextran. The results are
depicted in Fig. 4. In brief, 16HBE14o- CMLs were used
as reference control due to their known ability to form a
tight barrier [41]. As positive control, the CMLs were
additionally exposed to ethylenediaminetetraacetic acid
(EDTA), which causes the detachment of the CML fromFig. 4 Integrity assessment of A549 and MLE-12 CMLs by Blue Dextran assa
various time points at the ALI. (data are expressed as mean ± SD, n = 3 CM
° no significant difference, significant difference: * p < 0.05, ** p < 0.01)the membrane [42] and, hence, increases the transloca-
tion of Blue Dextran. Compared to 16HBE14o- CMLs,
the permeability of the A549 CML is marginally lower
and of MLE-12 CMLs slightly higher at all time points
at the ALI (24 to 96 h). However, a significantly in-
creased translocation through MLE-12 CMLs can only
be observed after 48 h at the ALI (p < 0.01). A detailed
discussion on the permeability to Blue Dextran and the
time course of the transepithelial electrical resistance
(TEER) is provided in Additional file 1.
Translocation kinetics
The influence of dose, size and incubation time on the
translocation kinetics of AuNP was assessed in order to
get a comprehensive picture of the translocation kinetics
of NPs across the epithelial tissue barrier (Fig. 5). The
translocation fraction was defined as the fraction of
AuNP that translocated from the surface liquid throughy. The translocation of Blue Dextran (2000 kDa) through the CMLs after
Ls; ┌─┐ indicates the significance level between two measurements,
Fig. 5 Translocation kinetics of AuNP through A549 and MLE-12 CMLs. (a) Translocation fraction of 18 nm AuNP after 24 h for different doses.
(b) Translocation fraction 24 h after exposure to 100 ng/cm2 AuNP for different sizes. (c) Translocation fraction of 18 nm AuNP at a dose of
100 ng/cm2 after different times post-exposure. The in vitro results were compared to in vivo data from Kreyling et al. [20] and Schleh et al. [30].
Kreyling et al. determined the translocation fraction of AuNP of various sizes after 24 h (b) and of 18 nm AuNP after various time points (c) in
female Wistar-Kyoto rats after intratracheal instillation. Schleh et al. determined the translocation fraction of 20 nm large AuNP in female C57BL/6
mice following two hours of inhalation exposure (c). (detailed information on properties and dose of the AuNP used in the in vivo studies may be
found in Additional file 1 (Table S1); data are expressed as mean ± SD, n = 3 (CMLs, # n = 2), n = 4 (rats/mice) and the yellow and blue areas show
the uncertainty range using Monte Carlo analysis (PBPK model, n = 1000 iterations); significant differences between A549 and MLE-12 CMLs:
* p < 0.05, ** p < 0.01)
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point post-exposure (Fig. 1).
In Fig. 5a, the translocation kinetics of AuNP through
A549 and MLE-12 CMLs are shown for different doses.
Both cell types have a similar translocation fraction of
around 2 %, which is independent of the applied dose up
to 100 ng/cm2, however, above this dose the translocation
fraction in A549 CMLs decreases significantly. These
dose-independent translocation kinetics up to 100 ng/cm2
make it possible to compare the translocation fractions of
CMLs (obtained at 25–100 ng/cm2) to in vivo data fromliterature (obtained at 0.2-8.63 ng/cm2 lung surface area,
see Additional file 1: Table S1) [20, 30].
In Fig. 5b, the translocation kinetics of AuNP through
A549 and MLE-12 CMLs are shown for different par-
ticle sizes. Also here, the translocation fractions are al-
most identical for A549 and MLE-12 CMLs 24 h post-
exposure, respectively. A significant difference in the
translocation fraction was only observed for 2 nm
AuNP, with a significantly higher translocation in mur-
ine cells when compared to human cells. The most im-
portant outcome, however, is that the size-dependent
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particle size and, although approximately one order of
magnitude higher, changes almost in parallel in the
in vitro measurements with the in vivo measurements
by Kreyling et al. [20].
In Fig. 5c, the translocation kinetics of AuNP through
A549 and MLE-12 CMLs are shown for different time
points post-exposure. For both cell types, a sharp in-
crease in the translocation fraction can be observed dur-
ing the first couple of hours, followed by a sharp
flattening between 8 and 24 h post-exposure. Between
24 and 72 h post-exposure the amount of translocated
AuNP is only increasing slowly. This change in the
translocation kinetics 24 h post-exposure may be an in-
dication that the AuNP follow different pathways
through the CMLs. The only significant difference be-
tween the translocation kinetics of the two cell lines is
the much higher translocation fraction that can be ob-
served in A549 CMLs two hours post-exposure. The
same sharp rise in A549 CMLs within the first two
hours post-exposure can also be seen in vivo for the
PBPK-adjusted translocation fractions based on Kreyling
et al. [20] and in the study by Schleh et al. [30]. The
slower rise in the translocation fraction within the first
couple of hours post-exposure in MLE-12 CMLs (i.e.,
the fraction of AuNP in the basolateral medium) is dir-
ectly related to the slower clearance of AuNP from the
surface liquid (Fig. 6a-b).
For comparison, we evaluated the translocation of
ionic gold through the CMLs and compared the results
to in vivo data for ionic gold from Kreyling et al. [20]
(Fig. 7a). No significant difference in the translocation
between any of the in vitro experiments and the bound-
ary levels for the in vivo studies was observed (Fig. 7a).
In all depicted cases, the translocation fraction of ionic
gold was around 75 %, which is very close to the trans-
location fraction that was observed for 2 nm AuNP
(A549: 54.2 ± 1.4 %; MLE-12: 71.0 ± 2.8 %; mean ± SD).
Finally, considering that a CML is a very simplified
cellular model of the lung epithelial tissue barrier, we
also compared the translocation kinetics of 18 nm AuNPFig. 6 Disposition of 18 nm large AuNP in the transwell chamber system. (
dose of 100 ng/cm2. The results of the translocated fraction (green areas) athrough A549 CML with a more sophisticated triple cell
co-culture (TCCC) system. In a TCCC system, macro-
phages and dendritic cells occupying the apical and basal
side of the alveolar epithelium, respectively, are also con-
tained in the cellular model [43]. As can be seen in
Fig. 7b, there is no significant difference between the
translocation of AuNP through the CML and the TCCC
system, hence, a CML is sufficient to model the trans-
location of the investigated AuNP through a cellular rep-
resentation of the air-blood barrier.
Transmission electron microscopy (TEM) images of
the A549 CML 24 h after exposure to 18 nm AuNP are
depicted in Fig. 8a-e. As can be seen, the particles are
mainly present as single particles or as small agglomer-
ates, consisting of only a few particles. Larger agglomer-
ates, such as in Fig. 8a, were only observed sporadically.
Particularly interesting is that the particles and agglom-
erates were freely distributed within the cytoplasm
(Fig. 8b-d) and are also observed close to the cell nu-
cleus (Fig. 8e). Particles in vesicles were not observed.
TEM images for the 2, 7 and 46 nm AuNP can be found
in Additional file 1. In brief, the 7 and 46 nm large parti-
cles showed the same distribution pattern as the 18 nm
AuNP (Additional file 1: Figure S7). The 2 nm AuNP
could not be distinguished from the background, even
though we prepared samples without lead citrate and ur-
anyl acetate staining. For 2 nm AuNP only one single
agglomerate was detected (Additional file 1: Figure S7).
PBPK modeling
As mentioned above, it was not possible to unambigu-
ously allocate the AuNP recovered in the feces in the
animal experiments to the two pathways biliary excre-
tion of AuNP (with translocation) and mucociliary clear-
ance of AuNP (without translocation) [20, 30] that were
compared to our CMLs set-up. Hence, in vivo the trans-
location fractions were calculated based solely on the re-
covered gold from secondary organs, making it difficult
to compare the in vivo data to the in vitro results pre-
sented in this paper. One way to overcome this problem
is PBPK modeling, which makes it possible to accounta) A549 and (b) MLE-12 CMLs after various time points at an exposure



















Fig. 7 Translocation of (a) ionic gold and (b) AuNP for two cell models of different complexity. (a) Comparison of the translocation fraction of ionic
gold after 24 h: CMLs treated with 100 ng/cm2 gold were compared to in vivo data from Kreyling et al. [20], who determined the biodistribution
in female Wistar-Kyoto rats after intratracheal instillation (1 μg gold). Two extreme scenarios are presented for the translocation fraction from
Kreyling et al. For the lower bound, we assumed that all of the gold that was recovered from the GIT and feces had not been translocated,
but instead had been cleared via the mucociliary pathway directly from the lungs to the GIT. For the upper bound, we assumed that all of
the gold in the GIT and the feces was first taken up and then cleared via the biliary pathway to the GIT. (b) Comparison of the translocation
fraction of 18 nm large particles in an A549 CML and a TCCC system 24 h after exposure to 100 ng/cm2 AuNP. (data are expressed as mean ± SD, n= 3
(CML/TCCC) and n= 4 (rats))
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cordingly the measured translocation fraction to yield
the total translocation of NPs from the lung to the blood
circulation.
In Fig. 5c, the adjusted translocation fractions for the
data of Kreyling et al. [20] are depicted up to 72 h after
intratracheal instillation of 18 nm AuNP in rats. The ad-
justed curve shows a sharp increase in the translocation
fraction during the first two hours post-exposure, whichFig. 8 TEM images of intracellular particles in the A549 CML. (a) Agglomer
and (e) particles next to the cell nucleus 24 h after exposure to 100 ng/cm
monolayer (top left) and the PET membrane on which the CML were grow
particles. (e: without lead citrate and uranyl acetate staining)is in good agreement with the translocation kinetics in
A549 CMLs. Steady state is reached approximately
three hours after exposure. In total, the adjusted trans-
location fraction is 3.9 times higher than the one originally
measured in vivo 24 h post-exposure. Unfortunately,
in vivo the translocation was only assessed up to 24 h
post-exposure, so it is not possible to confirm the
biphasic translocation kinetics observed in vitro with
in vivo data.ates, (b, c) small agglomerates and (d) single particles in the cytoplasm
2 18 nm AuNP in the ALICE system. In (b) and (c) the surface of the
n (bottom right) can be seen. The arrows are pointing towards the
Fig. 9 Comparison of the PBPK model to biokinetic data from female Wistar-Kyoto rats [20] 24 h after intratracheal instillation of various sizes of
AuNP. (only organs where the gold levels in all rats were above the LOD are depicted; data are expressed as mean ± SD, n = 4 (rats) and n = 1000
iterations (PBPK model), *unit for urine: % dose)
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of inhalation exposure from Schleh et al. [30] is also il-
lustrated. As can be seen, the in vivo translocation frac-
tion is in agreement with the translocation fractions
measured in A549 and MLE-12 CMLs 2 h post-
exposure. With the PBPK model it was further possible
to determine the complete time course of the transloca-
tion by fitting the translocation rate in the PBPK model
to the translocation fraction reported by Schleh et al.
[30]. The obtained time course is in good agreement
with the in vitro data of both cell types (Fig. 5c). The
measured translocation time course of the A549 CML
and the extrapolated translocation time course in mice
are practically identical, whereas MLE-12 differs during
the first 8 h post-exposure.
Finally, the 24 h post-exposure translocation fractions
of the 1.4, 2.8, 5 and 80 nm large AuNP were adjusted
by the same factor that was determined for the 18 nm
large AuNP with the PBPK model (Fig. 5b). These ad-
justed translocation fractions were further used to fit the
translocation rates and to simulate the biodistribution of
the AuNP with the PBPK model (Fig. 9; Note that the
18 nm data set cannot be considered independent, be-
cause it was already used to add the inhalation/instillation
pathway to the PBPK model and adjust the translocation
fractions of the other particle sizes). Although the biodis-
tribution is modeled size-independently in the PBPKmodel, all predicted organ and urine gold levels of all par-
ticle sizes fell close to the 1:1 line. Sole exceptions were
the kidneys’ and urine gold levels for the 1.4 nm and




AuNP were used as model NPs due to their low toxicity
[44–46], high stability under biologically relevant condi-
tions [20, 45], high electron density and the availability
of good quality in vivo studies [20, 30], which were used
to evaluate the predictive capability of our in vitro and
in silico results. Furthermore, to minimize the influence
of the coating on the translocation kinetics, the AuNP
were stabilized with citrate. Citrate is known to be easily
replaced by proteins in biological media [47, 48] such as
the surface liquid lining the CML and, thus, allows the
particles to quickly form a protein corona.
Choice of cell types
In contrast to primary cells, cell lines are often pre-
ferred due to the easy and reproducible use of cell cul-
tures as well as the purity of cell types. MLE-12 and
A549 cells were used, which are mouse and human al-
veolar type II like cell lines [33, 49], respectively, that
are well characterized and widely used as in vitro lung
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types is the production of surfactant [33, 34], however,
their relevance to study NP translocation is often ques-
tioned [50], because the expression of tight junction
proteins is not as pronounced as in other cell lines or
primary cells. The two cell lines used in the current
study were grown under controlled culture conditions
revealing a confluent and dense monolayer also when
cultured at the ALI as shown by the Dextran Blue trans-
location assay as well as by LSM images of the spatial cell
morphology. Especially at the ALI the cells show a denser
monolayer compared to cells cultured in suspension [51].
We also did not observe any NPs between cells, but al-
ways inside cells. Therefore their use to study the trans-
location of the here applied AuNPs seems to be justifiable.
Other cell lines such as the recently immortalized type II
cells that exhibit a type I like phenotype described by
Kemp and colleagues [52] or primary cells derived from
mice or human lung biopsies could, however, be consid-
ered in future studies.
Translocation kinetics
The determined translocation kinetics of AuNP through
A549 and MLE-12 CMLs are in good agreement with
kinetic data for AuNP in mice [30] and rats [20] in vivo.
This is particularly true for the size-dependent transloca-
tion kinetics, where the in vivo and in vitro curves are
almost parallel (Fig. 5b). Hence, exposing CMLs to NPs
in the ALICE system probably is an adequate model to
describe the translocation of NPs through the air-blood
barrier after short-term exposure. Further, there are four
notable observations that shall be discussed in more de-
tail below, namely, (1) the significantly different trans-
location fractions between A549 and MLE-12 CMLs two
hours after exposure in the ALICE system, (2) the sharp
decrease in the translocation efficiency of AuNP through
A549 CMLs at doses above 100 ng/cm2, (3) the higher
translocation fractions determined with the CMLs in the
ALICE system as compared to intratracheally instilled
AuNP in rats, and (4) the trend that the smaller the
AuNP become, the more their translocation kinetics
converge to the translocation kinetics of ionic gold.
The first two observations are probably related to the
different surface liquid heights between A549 and MLE-
12 CMLs. While the surface liquid height observed for
A549 CMLs is in good agreement with the height of
4.5 ± 0.7 μm (mean ± SD) that was reported previously
for primary human AT II cells [53], the observed surface
liquid height for MLE-12 CMLs is approximately four
times higher than measurements of Thompson et al.
[54] for primary rodent AT II cells (15 μm). This un-
physiologically high surface liquid height has a threefold
influence on the interaction between the NPs and the
cells [55, 56]. First, it prolongs the time that the particlesneed to sediment to the surface of the cells. Second, it
decreases the concentration gradient between the sur-
face liquid and the basolateral medium. Third, it affects
the likelihood for NPs to form agglomerates. In our ex-
periments, an increased sedimentation time and/or de-
creased concentration gradient is most likely responsible
for the significantly slower clearance of AuNP from the
surface liquid and consequently a lower translocation
fraction in MLE-12 CMLs as compared to A549 CMLs
two hours post-exposure. After the first two hours, the
translocation kinetics of both cell types are comparable
with each other, implying that it takes 2 h until the
AuNP get into contact with the MLE-12 CML due to
the unphysiologically high surface liquid height. Further-
more, the pattern for the translocation kinetics of AuNP
at different doses seems also to be related to the height
of the surface liquid, such that while the translocation
fraction in MLE-12 CMLs is the same up to the max-
imum investigated dose of 200 ng/cm2, there is a sharp
decrease of the translocation fraction in A549 CMLs
above a dose of 100 ng/cm2. A reason for this behavior
may be the higher particle concentration in the surface
liquid of A549 CMLs and hence a higher likelihood of ag-
glomeration at high doses. For example, Brandenberger
et al. [12] observed a larger amount of agglomerates in
A549 cells after exposure to 561 ng/cm2 AuNP (15 nm,
citrate-coated) in the ALICE system as compared to
61 ng/cm2 of the same particles. Also, as shown in our ex-
periments, the translocation efficiency is decreasing with
increasing particle diameter, which can be explained by
the size of the corona around the NPs, which changes in
the presence of biological fluids (e.g., lung liquid lining
layer), or by the formation of agglomerates. This observa-
tion clearly highlights the importance of experimental
in vitro set-ups that properly mimic the deposition of NPs
in the lung, such as the ALICE system, and illustrates that
unphysiological experimental conditions, such as sub-
mersed cultures, may bias the translocation kinetics of
NPs. In the present study we have observed single 18 nm
sized AuNP free in the cytoplasm, which is in agreement
with the study from Brandenberger et al. [12] who applied
a quantitative approach with TEM and found citrate-
stabilized AuNP of a similar size in the cytoplasm. How-
ever, the cytoplasm was not the preferred compartment
and the majority of the particles were found in vesicles.
The third important observation from our in vitro ex-
periments is that the translocation of AuNP across the
air-blood barrier of rats after intratracheal instillation is
overestimated by the CMLs, even though the transloca-
tion of AuNP across the air-blood barrier of mice after
inhalation exposure is well reflected by the CMLs. In
our opinion, this difference is not primarily linked to the
species used, i.e., mouse and rat, because our in vitro ex-
periments show that the translocation kinetics of AuNP
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ing that there is no species-specific mechanism for the
investigated AuNP. However, there are two factors that
have been reported before to influence the distribution
of particles in the lung and the pulmonary absorption of
these particles. Factor 1: the method of delivery may
greatly determine the distribution of particles in the
lung. After inhalation, the particles are usually much
more uniformly distributed within the lung as compared
to intratracheal instillation [57]. Hence, after intratra-
cheal instillation there might be regions in the lung with
relatively high particle densities, which may, as described
above, increase the likelihood of agglomeration and con-
sequently decrease the translocation of particles across
the air-blood barrier. Factor 2: the surface modification
of NPs may greatly influence the translocation of depos-
ited NPs across the air-blood barrier [19, 20, 27–29]. In
fact, in the in vitro and in vivo experiments discussed in
this work, different surface modifications have been
used. Schleh et al. [30] used unmodified AuNP (pro-
duced by a spark ignition generator), Kreyling et al. [20]
used sulfonated-triphenylphosphine-modified (1.4, 5, 18
and 80 nm) and thioglycolic-acid-modified (2.8 nm)
AuNP and we used citrate-modified AuNP. Although
the zeta potential is similar among all types of AuNP,
different surface modifications may lead to different
types of protein coronas. The protein corona largely de-
termines the biological properties of the NPs [35–37]
and, thus, has the potential to directly influence the
translocation kinetics. These considerations further ex-
plain the good agreement between our in vitro results
and the data from Schleh et al. [30], since citrate can
easily be replaced by proteins [47, 48] and, thus, it is not
surprising that citrate-modified AuNP behave similar to
unmodified AuNP. However, to fully understand the in-
fluence of the surface modification of NPs on the protein
corona and translocation kinetics across the air-blood
barrier more research is necessary.
The fourth, particularly interesting observation is that
the smaller the AuNP are, the more their translocation
kinetics are similar to the translocation kinetics of ionic
gold. The determination of the translocation pathways
across the CMLs was not within the focus of this work,
but the results suggest that very small NPs follow similar
or even the same pathways as ionic gold. So far, several
pathways have been described for different types of NPs
and different surface modifications, but these findings
are not substantial and consistent enough to link particle
properties to specific pathways. Yacobi and colleagues
[28, 29] used rat alveolar epithelial cell monolayers to in-
vestigate the translocation of polystyrene NPs at differ-
ent sizes (20 and 100 nm) and negative (carboxylate-
modified, sulfate-modified or aldehyde-sulfate-modified)
and positive (amidine-modified) surface charges. Theauthors came to the conclusion that the NPs primarily
follow transcellular pathways to traffic across the CML
and that the translocation takes place via diffusion. On
the contrary, for the same types of polystyrene NPs, dif-
ferent pathways have been proposed for mouse alveolar
epithelial cell monolayers [27]. While polystyrene NPs
with a positive surface charge mainly crossed the CML
via transcellular pathways, which involved clathrin- and
dynamin-dependent endocytosis, polystyrene NPs with a
negative surface charge followed paracellular and non-
endocytic transcellular pathways. In addition, for quantum
dots (negative surface charges, hydrodynamic diameter
25 nm) it was reported that they use para- and transcellu-
lar pathways to cross rat alveolar epithelial cell monolayers
[58]. Hence, the data indicates that the translocation does
not take place via endocytic pathways (i.e., caveolin-,
clathrin- and dynamin-mediated).
However, since all of these studies were carried out
with submerged cultures, the results cannot directly be
compared to our translocation data obtained at the ALI.
Still, a trend towards para- and transcellular diffusion is
apparent for negatively charged NPs. This trend is also
reflected in three ways in our data. First, the AuNP can
mainly be observed freely distributed in the cytoplasm
and not in vesicles. Second, the similar translocation
kinetics of A549 and MLE-12 CMLs, and the good
agreement between the in vitro and in vivo data indicate
that endocytic pathways, which may differ between spe-
cies, do not play an important role. Third, the transloca-
tion fraction was similar in an A549 CML and a TCCC
model, which also suggests a minor role of endocytic
pathways. Therefore, these results highlight that expos-
ure of CLMs at the ALI to NPs in the ALICE system is a
promising fast and cheap method to investigate the
translocation pathways of NPs across the lung epithelial
tissue barrier in more detail in the future. However, what
yet needs to be demonstrated with the presented model
is the capability to predict the translocation kinetics of
other types of NPs, e.g., those with positive surface
charge, and of agglomerates, for which the usage of
endocytic pathways across the lung epithelial tissue bar-
rier has been reported before [27, 59]. To enable this,
also more of reliable in vivo data are needed.
PBPK modeling
The disposition of AuNP in rats could successfully be
predicted with the PBPK model by using the permeabil-
ity of the different capillary wall types as a basis to
model the biodistribution of the NPs. Interestingly, the
same distribution and excretion rates as in our recently
presented PBPK model for TiO2 NPs [39] could be used,
which demonstrates that the biokinetics of both particle
types are very similar in vivo. Solely, the translocation
rate from the organs to the blood had to be slightly
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son for this difference is unknown, but since we could
already show that the size and surface modification have
a minor influence on the biodistribution of NPs [39, 60],
this difference might be simply related to the chemical
properties or to the concentration gradient between the
organs and the blood. However, since we could already
successfully model the biodistribution of AuNP, TiO2
NPs [39], silver NPs [60] and silicon dioxide NPs (un-
published data) with the same model structure by simply
varying the retention time of the particles in the organs,
this parameter may warrant further research.
Several observations that were made by Kreyling et al.
[20] on the biokinetics of AuNPs had already been sug-
gested by earlier studies with our PBPK model [39, 60]
and, thus, further confirm its validity. For instance, after
intratracheal instillation of negatively and positively
charged 2.8 nm AuNP in rats, the same biodistribution
resulted [20]. This behavior was also predicted with the
PBPK model. For silver NPs, it was possible to model
the biodistribution of polyvinylpyrrolidone (PVP) and
carboxymethyl cellulose coated and uncoated particles,
without considering the surface conditions in the model
[60]. Also, the size-independent biodistribution of AuNP
in vivo [20] was already observed with the PBPK model
for silver NPs [60]. However, the size-independent distri-
bution holds only true for low internal doses of NPs in
the PBPK model. At high internal doses, the uptake of
NPs by compartments of the mononuclear phagocytic
system, located in the liver, lungs and spleen [61], also
need to be considered in the model [39, 60]. This in-
creased distribution of NPs to the liver, lungs and spleen
seems to be dose- [62] and at high internal doses also
size-dependent [63] and can also be seen in vivo for
AuNP [64]. The reason for the different distribution pat-
terns observed for low and high internal doses remains
unknown, but as we have speculated before on the basis
of the results of the PBPK model this might be related
either to agglomeration or to a substantial alteration of
the protein corona due to a deficit of specific proteins at
high levels of NPs in the blood [39, 60].
Interestingly, the PBPK model could also be used to
model the biodistribution of AuNP that were smaller
than 15 nm, even though 15 nm had been previously de-
fined as the lower size limit of the model [60]. This limit
was based on the 6 to 15 nm capillary pore sizes of the
kidneys [65]. Below this size limit it was hypothesized
that NPs can translocate through the pores of the capil-
lary walls of the kidneys [39, 60] and, thus, very small
NPs are much easier transported to the kidneys and ex-
creted in urine [64, 66]. This behavior explains also the
underestimation of the in vivo kidneys’ and urine gold
levels [20] of the 1.4 nm and 2.8 nm AuNP by the PBPK
model. However, for the 5 nm AuNP this behaviorcannot be observed. This discrepancy can most likely be
attributed to the formation of a protein corona, which
increases the diameter in vivo. In fact, the reported crit-
ical diameter for an increased excretion of NPs in urine
was reported to be around 5 nm [64, 66] and, thus, con-
siderably below 15 nm. Nevertheless, apart from kidneys’
and urine gold levels of 1.4 nm and 2.8 nm AuNP, the
gold levels of all other organs could be predicted by the
PBPK model after intratracheal instillation of AuNP in
rats [20]. This shows that the model is in fact applicable
for NPs below 15 nm, but the levels in the kidneys and
the urine may be underestimated.
In the study of Kreyling et al. [20], the translocation
through the air-blood barrier was also investigated for
one particle size above the nano-range (200 nm). The
maximum particle size that can be described by the
model is 150 nm [60], and is based on the pore size of
the liver capillaries [65]. Hence, we have not included
particles above the nano-range in our experiments. Par-
ticles above this size limit may have difficulties passing
through the pores of the capillary wall of the liver and,
thus, it can be expected that they are hardly excreted via
the biliary pathway. In fact, this size threshold for the
biliary excretion of particles was already shown before for
intravenously injected AuNP in rats [64] and if this as-
sumption is considered in the PBPK model, the organ gold
levels of 200 nm large gold particles [20] can be predicted
well by the PBPK model (Additional file 1: Figure S11 and
S12). Based on these considerations, the comparably high
translocation of 200 nm AuNP through the air-blood bar-
rier that was reported by Kreyling et al. [20], may simply
be related to a decreased excretion efficiency and, thus, a
higher retention time for 200 nm large particles in the
body of the rat.
Conclusion
Our work shows how in vitro results obtained by CMLs
at the ALI can be combined with PBPK modeling to as-
sess the biokinetics of inhaled NPs. The time- and size-
dependent translocation of AuNP across the air-blood
barrier in animals is in good agreement with the results
obtained with the CMLs. The translocation kinetics are
well predicted for mice after inhalation exposure,
whereas for rats after intratracheal instillation, the trans-
location is slightly overestimated, which might be related
to the method of delivery or to the fact that different
surface modifications were used as compared to the
in vitro experiments. However, the very same variation
with size can be observed in the in vitro and in vivo data.
At exposure doses in the range of realistic exposures
(e.g., occupational exposure to 3 mg/m3 TiO2 NPs [67]
for a day), a dose-independent translocation of AuNP
across the CML can be observed. In addition, it was pos-
sible to demonstrate that there is hardly any difference
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indicating that pulmonary absorption does not differ be-
tween rodents and humans for the AuNP used (provided
that the NPs reach the same regions of the lung). The
smaller the NPs were, the more similar to ionic gold was
their disposition in the transwell chamber system. This
shows that very small NPs can cross the CML as easily
as ionic gold and, thus, indicates that they follow similar
or even the same pathways across the blood-air barrier.
The biodistribution of AuNP could successfully be de-
scribed with a PBPK model that was originally developed
for TiO2 NPs, and which used similar assumptions as a
PBPK model for silver NPs. This raises the question of
whether the biokinetics of inorganic NPs is generally
very similar in vivo. Also for AuNP, the biodistribution is
governed by the permeability of the different capillary
wall types. Several predictions regarding the biodistribu-
tion of NPs that were based on the PBPK model are fur-
ther supported by the data from Kreyling et al. [20].
Most importantly: (1) the minor influence of the surface
modification on the biodistribution, (2) an insignificant
uptake of particles by the phagocytic cells at low internal
exposure and (3) the size-independent biodistribution at
low internal exposure, except for increased uptake of
very small NPs (smaller than the capillary pores of the
kidneys) by the kidneys and excretion in the urine.
The most important outcome of this work is that
in vitro modeling of the pulmonary absorption with the
ALICE system in combination with the presented in
silico modeling of the biodistribution is closely reflecting
the in vivo behavior of AuNP. Hence, the presented ap-
proach has the potential to reduce short-term animal
studies, which aim to assess the pulmonary absorption
and biodistribution of NPs. Furthermore, the similar
translocation kinetics observed in in vivo and in vitro ex-
periments indicate that AuNP follow the same pathways
through the air-blood barrier in animals as observed for
the CMLs at the ALI. Hence, the presented setup may
be a relatively cheap and fast in vitro model to deter-
mine the translocation pathways of NPs through the air-
blood barrier, which is also suitable to assess the influ-
ence of e.g., the chemical composition, particle size and
shape, surface modification, aggregation/agglomeration




All investigated sizes of AuNP (2, 7, 18, 46, 80 nm) were
synthesized in our laboratory.
The 2 nm gold particles were synthesized immediately
before nebulizing in the ALICE. We followed the
method described by Yong et al. [68], but slightly
adapted it by the addition of sodium citrate (Fluka,Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). In
brief, 0.5 mL of freshly prepared 1 M NaOH (Merck,
Merck (Schweiz) AG, Zug, Switzerland) and 1 mL of tet-
rakis (hydroxymethyl) phosphonium chloride (THPC)
solution, obtained by adding 12 μL of 80 % THPC in
water (Sigma-Aldrich, Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) to 1 mL of millipore water, were
added to a beaker that contained 45 mL of millipore
water. The mixture was then magnetically stirred for
20 min at approximately 100 rpm. After the first 5 min
of stirring 10 mL of 5 mM chloroauric acid (HAuCl4°
3H2O, from gold (III) chloride trihydrate; Sigma-
Aldrich) and after 20 min 400 μL of 40 mM sodium cit-
rate was added. The final concentration was 170 μg/mL
for the 2 nm AuNP.
The 7 nm gold particles were prepared as described by
Jana et al. [69]. In brief, 2 mL of 40 mM sodium citrate
solution were mixed with 1.2 mL of 24.2 mM HAuCl4 in
90 mL of millipore water. 1 mL of ice-cold 20 mM so-
dium borohydride (NaBH4; Sigma-Aldrich) was added to
the stirred solution, which resulted in the formation of a
brownish red dispersion. Vigorous stirring of the gold
dispersion was continued for 5 min. After stirring, the
dispersion was washed by ultra-filtration at 4500 rpm
during 1 h, and redispersed in millipore water. The final
concentration was 300 μg/mL for the 7 nm AuNP.
The 18 nm gold particles were synthesized using cit-
rate to reduce Au3+ following the procedure of Grabar
et al. [70]. Briefly, the vigorously stirred aqueous tetra-
chloroauric acid solution (125 mL, 0.25 mM HAuCl4
3H2O) was brought to boiling, followed by rapid
addition of 12.5 mL of 40 mM sodium citrate to the vor-
texed HAuCl4 solution, which resulted in a color change
from pale yellow to dark wine red. The solution was
maintained at boiling temperature for 15 min and then
removed from heat. Stirring was continued for another
15 min. After the dispersion had cooled down to room
temperature, it was centrifuged at 4000 rpm for 30 min
and redispersed in millipore water. The final concentra-
tion was 200 μg/mL for the 18 nm AuNP.
The 46 and 80 nm gold particles were synthesized by
overgrowth of gold onto the 18 nm citrate-capped
AuNP (seed suspension), as described in [71]. For
46 nm AuNP, the growth step was carried out by
addition of hydroxylamine-hydrochloride (NH2OH∙HCl;
3 mL of 0.2 M; Sigma-Aldrich) and 18 nm citrate-
capped AuNP dispersion (15 mL) to a solution of
HAuCl4 (0.25 mM in 270 mL). For 80 nm AuNP, the
first growth step was carried out by the addition of
NH2OH∙HCl (3 mL of 0.2 M) to a solution of gold
HAuCl4 (0.25 mM in 270 mL of water) followed by
addition of the seed dispersion (18 nm AuNP; 30 mL)
resulting in spherical NPs of approximately 40 nm in
diameter. A second growth step was performed following
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trations: 0.25 mM of HAuCl4°3H2O, 3 mL of 0.2 M of
NH2OH∙HCl, and 30 mL of 40 nm AuNP. The resulting
AuNP were subsequently functionalized with sodium
citrate (1.7 mL of 40 mM sodium citrate) and washed by
centrifugation at 4000 rpm for 15 min, and 2500 rpm for
15 min, respectively, and redispersed in millipore water.
The final concentrations were 220 μg/mL and 200 μg/mL
for the 46 and 80 nm AuNP, respectively.
Characterization
UV–Vis spectra of the samples were recorded at 25 °C
using a Jasco V-670 spectrophotometer (Jasco Europe
S.R.L., Milano, Italy), using 10 mm path length quartz
cuvettes. As a first approximation, the particle size was
determined directly from UV–Vis spectra using the tab-
ulated theoretical data of uncoated spherical gold nano-
particles in water described in Haiss et al. [72]. The size
of the different AuNPs was qualitatively confirmed by
means of TEM. The surface charge of AuNP samples
was measured in suspension of 50 μg/mL in water at
25 °C using a phase amplitude light scattering (PALS) zeta
potential analyzer (Brookhaven Instruments Corporation,
Hotsville, NY, USA). The Smoluchowski approximation
[73] was fitted to 15 cycles of electrophoretic mobility
(EPM) measurements and 10 replicates were obtained for
each sample to estimate the mean and SD. Dynamic light-
scattering (DLS) measurements were carried out at room
temperature and at a scattering angle of 90°, using a 3D LS
spectrometer (LS instruments AG, Fribourg, Switzerland)
equipped with a 21 mW HeNe laser (632.8 nm). Data was
collected over 4 min, and five independent correlation
functions were measured. The corresponding correlation




The A549 cell line [34], a human AT II epithelial cell
line, was obtained from the American Tissue Type
Culture Collection (LGC Promochem, Molsheim, France).
Cells (passage number 8–20) were maintained in RPMI
1640 medium (with 25 mM HEPES; Gibco BRL, Life
Technologies, Basel, Switzerland) supplemented with
1 % L-glutamine (Gibco BRL), 1 % penicillin/streptomycin
(Gibco BRL) and 10 % foetal calf serum (PAA Laborator-
ies, Lucerna-Chem AG, Lucerne, Switzerland). For experi-
mental cultures, cells were seeded at a density of 0.5 x
106 cells/insert on transparent BD Falcon™ cell culture
inserts (surface area of 0.9 cm2, pores with 3.0 μm diameter,
PET membranes for 12-well plates; BD Biosciences, Basel,
Switzerland). Inserts were placed in BD Falcon™ tissue
culture plates (12-well plates; BD Biosciences) with 1 mL
medium in the upper and 2 mL in the lower chamber. Thecells were kept at 37 °C in 5 % CO2 humidified atmosphere
for 7 days (medium changed after 3–4 days).
MLE-12 monocultures
The MLE-12 cell line [33], a mouse AT II epithelial cell
line, was obtained from the American Tissue Type Cul-
ture Collection. Cells (passage number 7–25) were
maintained in advanced Dulbecco’s Modified Eagle
Medium: Nutrient mixture F-12 (DMEM/F12) medium
(Gibco BRL) supplemented with 1 % HEPES (Gibco BRL),
1 % insulin-transferrin-sodium selenite (Sigma-Aldrich),
1 % L-glutamine, 1 % penicillin/streptomycin, 10 nM
hydrocortisone (Sigma-Aldrich) and 10 nM β-estradiol
(Sigma-Aldrich). For experimental cultures, cells were
seeded at a density of 0.5 x 106 cells/insert on transparent
BD Falcon™ cell culture inserts (surface area of 0.9 cm2,
pores with 3.0 μm diameter, PET membranes for 12-well
plates). The cell culture inserts were pretreated with 45 μL
Matrigel coating solution, containing 3.36 mg/mL BD
Matrigel™ basement membrane matrix growth factor re-
duced (BD Biosciences) in Dulbecco’s modified Eagle
Medium (DMEM) medium (Gibco). Inserts were placed
in BD Falcon™ tissue culture plates (12-well plates) with
1 mL medium in the upper and 2 mL in the lower cham-
ber. The cells were kept at 37 °C in 5 % CO2 humidified
atmosphere for 3.5 days.
16HBE14o- monocultures
The 16HBE14o- cell line [75], a human bronchial epithe-
lial cell line, was kindly provided by Dieter Gruenert
(passage number P2.54; University California, San Francisco,
CA, USA). Cells (passage number 11) were maintained
in minimum essential media (MEM) 1x medium (with
Earle’s Salts, 25 mM HEPES and without L-glutamine;
Gibco BRL), supplemented with 1 % L-glutamine, 1 %
penicillin/streptomycin and 10 % foetal calf serum. For
experimental cultures, cells were seeded at a density of
0.5 x 106 cells/insert on transparent BD Falcon cell cul-
ture inserts (surface area of 0.9 cm2, pores with 3.0 μm
diameter, PET membranes for 12-well plates). The cell
culture inserts were pretreated with 150 μL fibronectin
coating solution, containing 0.1 mg/mL bovine serum
albumin (Sigma-Aldrich), 1 % bovine collagen Type I
(BD Biosciences) and 1 % human fibronectin (BD Biosci-
ences) in LHC Basal Medium (Sigma-Aldrich). Inserts
were placed in BD Falcon™ tissue culture plates (12-well
plates) with 1 mL medium in the upper and 2 mL in the
lower chamber. The cells were kept at 37 °C in 5 % CO2
humidified atmosphere for 7 days (medium changed after
3–4 days).
The triple cell co-culture (TCCC) system
A TCCC system with A549 alveolar epithelial cells and hu-
man blood monocyte derived macrophages and dendritic
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scribed before [43, 76]. Briefly, A549 CMLs were cultured
as described above. At 7 days, the medium was removed
from the upper and lower chamber, the inserts turned up-
side down and the bottom was abraded carefully with a cell
scraper. The inserts were then incubated with 150 μL
medium containing 125,000 dendritic cells on the basal
side of the CMLs for two hours. Afterwards, the nonadher-
ent cells were removed, the inserts turned around again
and placed in BD Falcon™ tissue culture plates (12-well
plates). In the lower chamber 2 mL of medium and at the
apical side of the CMLs 500 μL medium containing 25,000
macrophages was added. Once again the systems were in-
cubated for two hours to allow the macrophages to attach,
before nonadherent cells were washed away. The complete
TCCC systems were kept with 2 mL medium in the lower
chamber and 1 mL in the upper chamber at 37 °C in 5 %
CO2 humidified atmosphere for 24 h.
Air-liquid interface cell exposure system (ALICE)
Exposure
The medium in the upper chamber of the CMLs/TCCC
systems was removed 24 h prior to exposure in the
ALICE (to establish the ALI), the medium in the lower
chamber was replaced by 1 mL of fresh medium and the
basal side of the membrane was abraded carefully with a
cell scraper (only for CMLs). Exposure to NPs in the
ALICE was carried out as described elsewhere [12, 32].
Briefly, the ALICE consists of three main components: a
droplet generator (nebulizer), an exposure chamber and
a flow system with an incubation chamber providing
temperature and humidity conditions suitable for cell
cultivation. A dense cloud of micron-sized droplets is
generated by nebulization of 1 mL AuNP suspension
using a vibrating membrane droplet generator (Investiga-
tional eFlow, PARI Pharma GmbH, Munich, Germany).
The dense cloud of droplets generated by the eFlow
nebulizer is transported at a flow rate of 5 L/min into the
exposure chamber (20 × 20 × 30 cm) where it gently
deposits onto cells cultured at the ALI in standard cell
culture plates. Droplet deposition occurs due to single
particle sedimentation and an effect known as cloud set-
tling, i.e., the cloud of droplets moves like a bulk object ra-
ther than like a collection of individual droplets [32]. The
flow rate is chosen so that the cloud is diverted to all sides
by the ground plate of the exposure chamber to form an
almost symmetric pattern of vortices providing gentle, but
sufficient mixing to result in uniform special droplet
deposition on the cells. Following the exposure in the
chamber (which takes about 15 min), the basal sides of
the inserts were immediately washed thoroughly in
phosphate-buffered saline solution (PBS; Gibco BRL)
and placed in new BD Falcon tissue culture plates (12-
well plates), to avoid any cross contamination of AuNPthat could have diffused directly into the basolateral
medium via the gap between the well and the insert.
Afterwards, the cells were kept under ALI conditions in
5 % CO2 humidified atmosphere at 37 °C.
To obtain the desired exposure concentration, AuNP
suspensions were diluted with millipore water immedi-
ately before exposure. For the nebulization of ionic gold
an ICP standard solution (Fluka) was used.
Sample collection
For each exposure condition (cell line, dose, size and
time) the surface liquid, the cell monolayer and the
basolateral medium from three different inserts were
collected.
After exposure, the surface liquid, the cellular mono-
layer and the basolateral medium (Fig. 1) were collected
at various time points (0, 2, 8, 24, 48 or 72 h post-
exposure). First, the basolateral medium was collected.
Second, to segregate the surface liquid, the apical side of
the CML was rinsed twice with 300 μL PBS. At the end,
600 μL of trypsin-EDTA (0.05 %, with phenol red; Gibco
BRL) was placed on the apical side of the CML for ap-
proximately 20 min. Afterwards, both sides of the mem-
brane were rinsed thoroughly and the trypsin-EDTA
solution containing the detached cells was collected. The
obtained samples were stored in 1.5 mL Eppendorf tubes
in the freezer until they were further processed to quan-
tify the distribution of gold in the system.
Every 24 h, the basolateral medium was replaced by
fresh medium and the old medium was also stored in
the freezer until the samples were further processed (i.e.,
for the 48 and 72 h post-exposure CMLs). The amount
of gold in the basolateral medium of each day was
summed up to determine the total translocation fraction.
A significant influence of the medium replacement on
possible saturation effects can be ruled out because the
basolateral medium compartment is several times larger
than the surface liquid and CML compartment com-
bined and, thus, the concentration of AuNP in the baso-
lateral medium is at all times much lower than in the
CML compartment.
Surface liquid height
The surface liquid height of the CMLs was quantified by
determining the liquid volume with the pipette after
24 h at the ALI. The results represent the mean of the li-
quid volumes of ten CMLs.
The translocated <30 kDa fraction
To assess the stability of the AuNP, the <30 kDa fraction
in the basolateral medium from three A549 CMLs 24 h
post-exposure was determined. To this end, a centrifugal
concentrator with a 30 kDa cutoff filter (Sartorius Vivas-
pin 2, Sartorius AG, Goettingen, Germany) was used.
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The amount of gold in the basolateral solution of the
membrane was measured using inductively coupled
plasma mass spectrometry (ICP-MS) as described below.
The efficiency of the procedure was determined by spik-
ing a 1 mL RPMI medium supplemented as described
above with 34 ng gold (gold standard for ICP; Fluka)
and comparing the ICP-MS measurements of the spiked
samples before and after filtration. As a worst case con-
sideration, the difference in the recovery efficiency be-
fore and after filtration was used to correct the
translocated <30 kDa fractions.
Inductively coupled plasma mass spectrometry (ICP-MS)
Sample preparation
To determine the total amount of settled AuNP in the
ALICE, three wells of the BD Falcon™ tissue culture
plates were kept completely empty during exposure.
These empty wells were rinsed thoroughly with 1 mL of
aqua regia. The aqua regia solutions were then left over-
night on the shelf under the fume hood in 15 mL tubes
before they were diluted with millipore water to 3 mL
for the ICP-MS measurement.
Samples (surface liquid, cellular monolayer and the baso-
lateral medium) were heated up to 70 °C and treated with
500 μL HNO3 (Sigma-Aldrich). After two hours at 70 °C,
the samples were placed in 15 mL tubes (BD Falcon
Conical Tubes, BD Biosciences), supplemented with
500 μL of aqua regia (HCl (Fluka)/HNO3 = 1/3, volume
ratio) and left overnight on the shelf under the fume hood
before they were diluted with millipore water to 3 mL for
the ICP-MS measurement. Compared to the settled
amount of AuNP in the empty wells, the average recovery
rate was approximately 80 % and 75 % for A549 and MLE-
12 CMLs (total transwell chamber system), respectively.
Measurement
ICP-MS analyses were carried out on an Agilent 8800
ICP-MS (Agilent Technologies, Waldbronn, Germany)
using an external calibration curve (1000 μg/ml gold
standard for ICP; Merck) with internal standardization
(1000 μg/ml iridium standard for ICP; Merck). The instru-
ment is equipped with two quadrupole mass analyzers
(MS/MS) and a collision/reaction cell. Rinsing was done
with 1 % HNO3/2 % HCl between each measurement.
The LOD of the ICP-MS corresponded to a dose of
25 ng/cm2. With lower doses it was not possible to reli-
ably determine the translocated AuNP fraction in the
basolateral medium 24 h post-exposure.
Epithelial membrane integrity tests and cell morphology
Laser scanning microscopy (LSM)
The CMLs were labelled and scanned as described in
earlier publications [13, 77]. Briefly, CMLs were washedin PBS and fixed for 15 min at room temperature in 4 %
paraformaldehyde (Sigma-Aldrich) in PBS. Fixed cells
were permeabilized in 0.2 % Triton X-100 (Fluka) in PBS
for 15 min. The CMLs were incubated with the anti-
bodies at room temperature for two hours. The cytoskel-
eton (F-actin-filaments) was stained with rhodamine
phalloidin 1:50 (R-415; Molecular Probes, Life Technolo-
gies Europe B.V., Zug, Switzerland) and the DNA was
stained with DAPI 1:100 (Sigma Aldrich). Afterwards,
preparations were washed three times in PBS and mounted
in Glycergel (Dako Schweiz AG, Baar, Switzerland).
A Zeiss LSM 710 Meta with an inverted Zeiss micro-
scope (Axio Observer.Z1, Lasers: HeNe 633 nm, and Ar
488 nm; Carl Zeiss AG, Feldbach, Switzerland) was
used. Image processing and visualization was performed
using IMARIS, a three-dimensional multi-channel image
processing software for confocal microscopic images
(Version 7.4.2; Bitplane AG, Zurich, Switzerland). To
visualize the surfaces of the CMLs, a shadow projection
was applied.Permeability to Blue Dextran
After 24 h at the ALI, the medium at the basal side of
the CML was replaced by 1 mL RPMI medium (without
phenol red; Gibco BRL) supplemented with 10 % foetal
calf serum. At the apical side of the CML 250 μL of that
medium and 250 μL of 1 % Blue Dextran (GE Health-
care; VWR International GmbH, Dietikon, Switzerland)
in PBS was placed. For the positive control group, RPMI
medium (without phenol red) and 20 mM of EDTA
(Sigma-Aldrich) was used. The CMLs were then incu-
bated at 37 °C in 5 % CO2 humidified atmosphere for
two hours. Afterwards, the basolateral medium was col-
lected and the mean absorbance at 600 nm was measured
in triplicate using a Micro-plate Reader (Benchmark Plus;
Bio-Rad Laboratories AG, Cressier, Switzerland). In total,
the translocation through three CMLs was determined for
each cell type. The absorbance was normalized to the
translocation of Blue Dextran through an empty insert.Transepithelial electric resistance (TEER) measurements
TEER was measured with the Millicell-ERS system
(MERS 000 01; Millipore AG, Volketswil, Switzerland) as
described in earlier publications [43, 77]. The mean of
three measurements per insert was determined and in
total ten inserts per cell line were assessed daily (five in-
serts without exposure and five inserts with exposure in
the ALICE). Before each measurement the CMLs were
allowed to equilibrate for 15 min at room temperature
in the biological safety cabinet. The electrical resistance
of inserts without cells was subtracted from all samples,
and the resistance values were multiplied with the sur-
face area of the inserts (0.9 cm2).
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Particle diameter before and after ALICE exposure
TEM images were obtained using a Tecnai F20 (FEI,
Eindhoven, The Netherlands) equipped with an Ultra-
Scan 1000XP 2 k CCD camera (Gatan Inc., Pleasanton,
CA, USA). To determine the particle diameters after
nebulization in the ALICE system, standard TEM copper
mesh grids were placed at the bottom of the ALICE.
The images were analyzed automatically using ImageJ
for Windows (Version 1.48a; National Institute of
Health, Bethesda, MD, USA). By applying the watershed
algorithm the individual particles were identified, and
then the major diameter and circularity were automatic-
ally determined.
Intracellular particles
Intracellular particles were visualized by conventional
TEM as described before [12]. For TEM analysis, the ex-
posed cells on the transwell membrane were fixed with
2.5 % glutaraldehyde (Sigma-Aldrich) in 0.15 M HEPES
buffer for at least 24 h. Then they were washed with
HEPES buffer, post-fixed with 1 % osmium tetroxide in
sodium cacodylate buffer, washed with maleate buffer,
and stained en bloc with 0.5 % uranyl acetate in maleate
buffer. Afterwards, the cells were dehydrated in ascend-
ing ethanol series, and embedded in Epon. From the
embedded cells, ultrathin sections were cut parallel to
the vertical axis of the cells and mounted on copper
grids, stained with lead citrate and uranyl acetate. TEM
images were obtained using a Morgagni 268 (FEI).
Statistics
An independent groups t-test was performed to compare
the mean translocation fractions between two CMLs. To
this end, the Statistics Calculator for Windows (Version
4.0; StatPac, Inc., Bloomington, MN, USA) was used.
The criterion for statistical significance was p ≤ 0.05.
Physiologically based pharmacokinetic (PBPK) modeling
The PBPK model for AuNP (Fig. 2) was adapted from our
recently presented PBPK model for TiO2 NPs [39]. The
only changes made were the addition of the inhalation/
instillation pathway, the harmonization of the investigated
organs/compartments with the data of Kreyling et al. [20]
and the modification of one kinetic rate (i.e., the transloca-
tion rate from the organ to the blood). A detailed descrip-
tion of the PBPK model can be found in Additional file 1.
In brief, the main idea of the PBPK model is that organs
with the same capillary wall type (i.e., the non-sinusoidal
non-fenestrated blood capillary type, the non-sinusoidal
fenestrated blood capillary type and the sinusoidal blood
capillary type, respectively) have the same uptake rate for
nanoparticles and that the biodistribution via this transca-
pillary pathway is size-independent. A sensitivity analysisfor the model structure can be found in the Supplemental
Information for Bachler et al. [39], which reveals that the
most sensitive parameters are the blood flow to the re-
spective organs and the translocation constants. For the
here-discussed AuNP-model also the translocation rates
from the lung deposition compartment will be among the
most sensitive parameters.
For all calculations with the PBPK model an uncertainty
analysis was conducted using a Monte Carlo simulation
(1000 iterations). To this end, log-normal distributions
were used for the physiological and compound-dependent
parameters, which were changed randomly in each iter-
ation within their given distributions. A full list of parame-
ters, along with the associated equations is given in
Additional file 1.
Additional file
Additional file 1: Supplementary Material. Contents: Chapter 1:
Additional data on the AuNP characterization: UV–Vis spectra, size
distribution histograms, TEM images and physicochemical parameters
and dose metrics of the in vivo studies that were compared to the CMLs.
Chapter 2: Additional data on the CML characterization: LSM images of
the CMLs after 72 and 96 h at the ALI and an in-detail discussion on
the integrity test with Blue Dextran. Chapter 3: Additional data on the
translocation kinetics: Estimation of the number of AuNP per cell
exposed and the time-, size- and dose-dependent disposition of the
AuNP between the three compartments of the transwell chamber
system. Chapter 4: Additional data on the PBPK model: Model methodology,
parameterization, parameters, equations and assumptions. And, the
predicted translocation fraction and biodistribution of 200 nm gold
particles in rats 24 h after intratracheal instillation and the predicted
biodistribution of 20 nm AuNP in mice after two hours of inhalation
exposure.
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